Integrated Filling(Audited) for the quarter and year ending 31st March, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem India reported audited results for FY25 with revenue from operations rising sharply to Rs. 38,623 lakhs from Rs. 23,348 lakhs in FY24, a growth of about 65% year-on-year. However, profit after tax collapsed to Rs. 46 lakhs from Rs. 276 lakhs in FY24, reflecting heavy cost pressures with cost of materials and GST expenses both rising steeply. The company raised Rs. 33.87 crore through a preferential issue in Feb–Mar 2025, with the original plan being Rs. 81.83 crore; the funds are earmarked for repayment of security deposit, capex, working capital, and general corporate purposes, though utilization till March 31 was minimal (only Rs. 9.52 lakh used for working capital). The statutory auditor issued an unmodified (clean) opinion on the standalone results. Total borrowings are nil and there are no defaults on loans or debt securities.
Despite strong top-line growth, sharply lower profit and negative operating cash flow of Rs. 10.09 crore raise concerns about profitability and working capital health. Shareholders should note the muted earnings despite higher sales, but the clean audit, zero debt, and fresh equity infusion of Rs. 33.87 crore provide some balance sheet cushion for the company's expansion plans.